RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the
underwriters of its recent public offering of its common stock have
exercised in full their option to purchase an additional 600,000 shares.
The total gross proceeds from this offering to BioCryst, including from
the exercise of the over-allotment option, are expected to be $20.2
million, before deducting underwriting discounts and commissions and
other estimated offering expenses payable by BioCryst. BioCryst expects
to use net proceeds of this offering for general corporate purposes,
including funding clinical development of BCX4161,
continued development of second generation hereditary angioedema
compounds and pre-commercialization activities related to intravenous peramivir.
The offering, including the sale of the additional shares, is expected
to close on August 6, 2013, subject to customary closing conditions.
Wells Fargo Securities, LLC and JMP Securities LLC acted as joint
book-running managers, and Noble Financial Capital Markets acted as
co-manager for the offering.
The shares of common stock described above are being offered by BioCryst
pursuant to a shelf registration statement previously filed with and
declared effective by the U.S. Securities and Exchange Commission. A
final prospectus supplement related to the offering was filed with the
SEC and is available on the SEC's website located at http://www.sec.gov.
Copies of the final prospectus supplement and the accompanying
prospectus relating to this offering may be obtained from Wells Fargo
Securities, LLC, 1525 West W.T. Harris Boulevard, NC0675, Charlotte, NC
28262, Attn: Capital Markets Client Support, telephone: 1-800-326-5897
or email: cmclientsupport@wellsfargo.com;
or JMP Securities LLC, Attn: Prospectus Department, 600 Montgomery
Street, 10th Floor, San Francisco, CA 94111, telephone: 1-415-835-8985.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, these securities, nor will there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale is not permitted.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small
molecule drugs that block key enzymes involved in infectious and
inflammatory diseases, with the goal of addressing unmet medical needs
of patients and physicians. BioCryst currently has two late-stage
development programs: peramivir, a viral neuraminidase inhibitor for the
treatment of influenza, and ulodesine,
a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of
gout. In addition, BioCryst has several early-stage programs: BCX4161
and a next generation oral inhibitor of plasma kallikrein for hereditary
angioedema and BCX4430,
a broad spectrum antiviral for hemorrhagic fevers. For more information,
please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including
statements regarding future results and achievements. These statements
involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements.
Please refer to the documents BioCryst files periodically with the SEC
and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
BioCryst Pharmaceuticals
investors & media:
Robert
Bennett, +1-919-859-7910
Source: BioCryst Pharmaceuticals, Inc.
News Provided by Acquire Media